POLIVY® 三國會 Tri-Affiliate Meeting (Germany/South Korea/Taiwan)

Date

July 18, 2020

Time

14:30~17:10

Venue

台北喜來登飯店 B2喜廳（台北市忠孝東路一段12號）
President of the Hematology Society of Taiwan

Jih-Luh Tang 唐季祿

Experience
  • President of the Hematology Society of Taiwan
  • Attending physician in Division of Hematology at National Taiwan University Hospital
Research Interests
  • Internal Medicine
  • Hematology and oncology
  • Bone marrow transplantation
  • Molecular Biology
Education
  • College of Medicine, National Taiwan University
  • PhD, Institute of Clinical Medicine, National Taiwan University
  • Post-doctoral fellowship, The University of Texas Health Science Center at Houston
Director of Division of Hematology at MacKay Memorial Hospital

Ming-Chih Chang 張明志

Experience
  • Director of division of hematology at MacKay Memorial Hospital
  • Attending physician in division of hematology at MacKay Memorial hospital
Research Interests
  • Leukemia
  • Lymphoma
  • Hematology and oncology
  • Metastatic cancer
  • Gastrointestinal cancer
  • Lung Cancer
  • Breast Cancer
Education
  • College of Medicine, Taipei Medical University
President of Taiwan Society of Blood and Marrow Transplantation

Bor-Sheng Ko 柯博升

Experience
  • President of Taiwan Society of Blood and Marrow Transplantation
  • Attending physician in Division of Hematology at National Taiwan University Hospital
Research Interests
  • Leukemia
  • Lymphoma
  • Hematology and oncology
Education
  • College of Medicine, National Taiwan University
  • PhD, Institute of Clinical Medicine, National Taiwan University

Speaker from Germany

Prof. Georg Lenz

Director of the Department of Haematology, Oncology and Pneumology at the University Hospital in Münster, Germany

  Professor Georg Lenz started his career as a medical doctor in Münster in 2002 and completed his post-doctoral fellowship at the National Cancer Institute in Bethesda, USA. In 2009, he moved to Berlin and continued his scientific career as Professor of "Molecular pathogenesis of malignant lymphomas" at the Charité - Universitätsmediyin Berlin, where he also worked as a Senior Physician at the Medical Clinic of Haematology, Oncology and Tumour Immunology until 2014.

  His researches focus on the molecular characterization of malignant lymphomas. Clinically he focuses on trials investigating the efficacy of novel compounds in the therapy of patients with haematological malignancies.

  He has published numerous articles in peer-reviewed journals such as the New England Journal of Medicine, Science, Nature, Blood, Journal of Clinical Oncology , and he has authored several books and book chapters.

Speaker from South Korea

Prof. Tae Min Kim

Associate Professor in Department of Hematology, Medical Oncology at the Seoul National University Hospital, Korea

  Professor Tae Min Kim is a specialist of lymphoid malignancies – both as a doctor and as a scientist. His patients benefit from his research as he translates his scientific findings into the clinic.

  Dr. Tae Min Kim graduated from Seoul National University and has done his residency training in the Department of Internal Medicine at Seoul National University Hospital (SNUH). He has done his clinical fellowship as well as being a clinical instructor, assistant professor and currently being the associate professor in the Division of Hematology and Medical Oncology in the Department of Internal Medicine at SNUH.

  Dr. Kim's clinical interests are lung cancer, malignant lymphoma, sarcoma, brain tumor, and melanoma. In addition, Dr. Kim is conducting clinical trials for these tumors and he is interested in a translational research for malignant lymphoma and lung cancer as well as an Immuno-Oncology.

Main clinical trials of Roche GO29365 (Pola+BR in R/R DLBCL), POLARIX, GO40515 (Mosunetuzuamb in DLBCL) 

Speaker from Taiwan

Dr. Cheng-Hong Tsai

Attending physician at Tai-Cheng Stem Cell Therapy Center in National Taiwan University, Taiwan

  Dr. Cheng-Hong Tsai graduated from National Taiwan University and now is a PhD candidate in Genome and System Biology degree program from National Taiwan University and Academia Sinica.

  He has done his clinical fellowship training in hematology as well as being a clinical lecturer in the Department of Internal Medicine. Dr. Tsai is an attending physician at Tai-Cheng Stem Cell Therapy Center in National Taiwan University as well as the deputy secretary general in Taiwan Society of Blood and Marrow Transplantation.

  Dr. Tsai’s clinical interests are hematology malignancies, aplastic anemia and hematopoietic stem cell transplantation.

POLIVY®

polatuzumab vedotin